192 related articles for article (PubMed ID: 37630190)
21. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
Gard PR
Expert Opin Ther Targets; 2004 Feb; 8(1):7-14. PubMed ID: 14996614
[TBL] [Abstract][Full Text] [Related]
22. Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease.
Koronyo-Hamaoui M; Sheyn J; Hayden EY; Li S; Fuchs DT; Regis GC; Lopes DHJ; Black KL; Bernstein KE; Teplow DB; Fuchs S; Koronyo Y; Rentsendorj A
Brain; 2020 Jan; 143(1):336-358. PubMed ID: 31794021
[TBL] [Abstract][Full Text] [Related]
23. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Wallis EJ; Ramsay LE; Hettiarachchi J
Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
[TBL] [Abstract][Full Text] [Related]
24. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
25. Medical genetics-based drug repurposing for Alzheimer's disease.
Zhang XZ; Quan Y; Tang GY
Brain Res Bull; 2015 Jan; 110():26-9. PubMed ID: 25446738
[TBL] [Abstract][Full Text] [Related]
26. Conversion of Aβ43 to Aβ40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme.
Liu S; Liu J; Miura Y; Tanabe C; Maeda T; Terayama Y; Turner AJ; Zou K; Komano H
J Neurosci Res; 2014 Sep; 92(9):1178-86. PubMed ID: 24823497
[TBL] [Abstract][Full Text] [Related]
27. The brain RAS and Alzheimer's disease.
Wright JW; Harding JW
Exp Neurol; 2010 Jun; 223(2):326-33. PubMed ID: 19782074
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders.
Santiago TC; Parra L; Nani JV; Fidalgo TM; Bradshaw NJ; Hayashi MAF
J Neurochem; 2023 Jul; 166(2):138-155. PubMed ID: 36908214
[TBL] [Abstract][Full Text] [Related]
29. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease.
AbdAlla S; Langer A; Fu X; Quitterer U
Int J Mol Sci; 2013 Aug; 14(8):16917-42. PubMed ID: 23959119
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Song JC; White CM
Clin Pharmacokinet; 2002; 41(3):207-24. PubMed ID: 11929321
[TBL] [Abstract][Full Text] [Related]
31. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits.
Li J; Hirose N; Kawamura M; Arai Y
Atherosclerosis; 1999 Apr; 143(2):315-26. PubMed ID: 10217360
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline.
Bernstein KE; Koronyo Y; Salumbides BC; Sheyn J; Pelissier L; Lopes DH; Shah KH; Bernstein EA; Fuchs DT; Yu JJ; Pham M; Black KL; Shen XZ; Fuchs S; Koronyo-Hamaoui M
J Clin Invest; 2014 Mar; 124(3):1000-12. PubMed ID: 24487585
[TBL] [Abstract][Full Text] [Related]
33. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias.
Davies NM; Kehoe PG; Ben-Shlomo Y; Martin RM
J Alzheimers Dis; 2011; 26(4):699-708. PubMed ID: 21709373
[TBL] [Abstract][Full Text] [Related]
34. Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues.
Torsello A; Bresciani E; Ravelli M; Rizzi L; Bulgarelli I; Ricci G; Ghiazza B; Del Puppo M; Mainini V; Omeljaniuk RJ; Tamiazzo L; Mancia G; Magni F; Locatelli V
Pharmacol Res; 2012 Oct; 66(4):317-24. PubMed ID: 22732396
[TBL] [Abstract][Full Text] [Related]
35. Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.
Saavedra JM
Cell Mol Neurobiol; 2016 Mar; 36(2):259-79. PubMed ID: 26993513
[TBL] [Abstract][Full Text] [Related]
36. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population.
Rygiel K
J Postgrad Med; 2016; 62(4):242-248. PubMed ID: 27763482
[TBL] [Abstract][Full Text] [Related]
37. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibitors: a comparative review.
Raia JJ; Barone JA; Byerly WG; Lacy CR
DICP; 1990 May; 24(5):506-25. PubMed ID: 2188439
[TBL] [Abstract][Full Text] [Related]
39. Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis.
Ye R; Hu Y; Yao A; Yang Y; Shi Y; Jiang Y; Zhang J
Int J Clin Pract; 2015 Jun; 69(6):674-81. PubMed ID: 25721930
[TBL] [Abstract][Full Text] [Related]
40. Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives.
Regenold WT; Blumenthal JB; Loreck DJ; Mordecai KL; Scarinzi G; Doddi SR; Adler L
Am J Alzheimers Dis Other Demen; 2017 Sep; 32(6):347-352. PubMed ID: 28449585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
